Immunovant
Prezzo: 33.62Società e modello di business
Immunovant is a biotechnology company focused on developing innovative therapies for autoimmune diseases. Its core product is IMVT-1401, a monoclonal antibody designed to treat conditions such as myasthenia gravis. The company primarily operates in the healthcare sector, with its main revenue source being potential future sales of its therapeutic products. Immunovant is currently in the clinical development stage, with no commercialized products generating revenue.
Profilo di investimento
The investment profile of Immunovant is more aligned with growth investors due to its focus on developing new therapies and the potential for significant future revenue, albeit with high associated risks. The stock may not appeal to dividend or value investors given the lack of current profitability and established revenue streams.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -2.78 Rischio
- Sorpresa EPS
- -21.7% peggio del previsto
- Volatilità 20g
- 8.4% normal
Impatto della previsione
neutraleTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-13 02:40 | Vendi | Mantieni | Positive momentum, but fundamentals show significant weakness. |
| 2026-06-03 02:43 | Mantieni | Vendi | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 02:48 | Vendi | Mantieni | Strong recent performance, but fundamentals remain weak. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-21 10:35 | H.C. Wainwright | Target alzato | — → 40 | 35.56 |
| 2026-01-06 12:55 | Wolfe Research | Rating migliorato | — → 50 | 24.97 |
| 2025-12-18 13:29 | Guggenheim | Target abbassato | 44 → 41 | 26.2689 |
Ancora nulla